Abstract: An oral film comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one base or salts or hydrates thereof.

Abstract: The invention relates to a conveyor device having a filling device (7) for vertical flow of material, without demixing, of powdered media having different particle sizes and particle densities, having the following features: a supply container (8) having a lower opening (9) to which the filling device (7) can be coupled; an inlet hopper (1) having an upper inlet opening (10) and a lower outlet opening (11) of a guide tube (12), the inlet opening (10) being couplable to the lower opening (9) of the supply container (8); telescopic elements (13), which are arranged on the guide tube (12), and an outlet hopper (3) having an outlet flap (4).

Abstract: The invention relates to an active-ingredient-containing, matrix-controlled transdermal therapeutic system for the use of pramipexole, ropinirole, pharmaceutically acceptable salts thereof or pharmaceutically acceptable derivatives thereof.

Abstract: This present invention concerns a cover layer that is impermeable to the active substances and/or a removable protective layer of a transdermal therapeutic system, comprising a thermoplastic film which either directly contains the absorbing agents and channel-forming agents or is coated with a polymer support (thermoplast) containing these substances. The polymer support can either be applied over the entire surface of the film or in patterns, directly during production. The thermoplastic film that is used and the polymer support can be made from either the same or different materials.

Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Abstract: The invention relates to pharmaceutical combination preparations with synergistic action for the treatment of migraine. Said preparations contain plant-based components and/or preparations of Tanacetum parthenium in combination with Vitex agnus castus and/or Cimicifuga racemosa and/or Zingiber officinale as their pharmaceutically active ingredients. The combination preparation provided for in the invention is suitable for the treatment of not only the headache but also the other symptoms of migraine while avoiding the usual side-effects.

Abstract: The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying &agr;-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

Abstract: This invention relates to a transdermal system containing fentanyl as the active ingredient and consisting of or comprising

Abstract: The invention relates to a patch for transdermal application of pergolid and its pharmaceutically acceptable salts.

Abstract: The invention relates to a solid, sustained-release pharmaceutical composition for oral administration containing tilidine mesylate as active ingredient.

Abstract: The invention relates to a novel pharmaceutical combination comprising clindamycin and clotrimazole for use for vaginal infections.

Abstract: The invention relates to a patch-shaped object, for example a TTS, patch, sticker or label, where the object comprises or is formed by an adhesive layer and a cover foil covering the adhesive layer having the same surface dimensions. The object further comprises a peeling foil temporarily covering the oppositely opposed side of the adhesive layer where the peeling foil extends beyond the patch-shaped object on all sides to form a border, the border having two recesses disposed at a spacing apart from one another. The end points of a break line formed in the peeling foil and passing over the object joins into each of the recesses.

Abstract: A transdermal patch contains an active loratidine metabolite contained with polyacrylate polymer matrix. The transdermal patch provides pharmaceutically useful transdermal flux rates over time.

Abstract: The invention relates to a transdermal system containing at least one angiotensin-converting enzyme inhibitor.

Abstract: Pharmaceutical compositions containing enolic carboxamide type antiinflammatory agent meloxicam that exhibit improved wettability, aqueous solubility, dissolution behaviour over a broad range of pH, and that are prepared by crystal structure modification of the drug through dry or wet mechanical homogenization with two further components—one of them is selected from a group of oligo—and dissolution improving, or alkalizing agent. The application of the formulations according to the present invention results in an improved biovailability and effectiveness of meloxicam.

Abstract: The invention relates to a pharmaceutical preparation which comprises or consists of the following components: (i) an initial dose of active ingredient, which is provided by the active ingredient together with optional excipients, (ii) a first delayed-release type of pellet, in which the active ingredient and optional excipients are covered with a coating, and (iii) a second delayed-release type of pellet, in which the active ingredient and optional excipients are again covered with a coating, wherein the active ingredient is an ACE inhibitor, and wherein the amounts of the coatings according to (ii) and (iii) are present in a ratio, based on weight, within the range of from 1:2 to 1:7.

Abstract: A pharmaceutical formulation comprising a benzimidazole derivative as active ingredient, and as excipients, at least one cyclodextrin and at least one amino acid.